Pre-market Hot Trades in US Stocks
Chanson is down 22.48% in pre-market trading. Based on recent key news:
<ol>
<li>
On April 26, analysts rated Chanson International as a sell. Top analysts at MarketBeat believe there are five stocks more worthy of purchase than Chanson, leading to a decline in investor confidence and a significant drop in stock price.
</li>
<li>
On April 26, Chanson International failed to make the list of stocks recommended by top analysts. Analysts believe that five other stocks have greater investment value, further undermining market confidence in Chanson and causing the stock price to fall.
</li>
<li>
No other significant news recently. Analyst ratings have a significant impact, and market confidence is lacking.
</li>
</ol>
Intellia Therapeutics is up 22.26% in pre-market trading. Based on recent key news:
<ol>
<li>
On April 24, Intellia announced that it will release the topline results of its global Phase 3 HAELO trial involving lonvoguran ziclumeran for the treatment of hereditary angioedema on April 27. This news is seen as a potential milestone for its platform clinical validation, driving the stock price up.
</li>
<li>
On April 24, Intellia's stock price rose 19.27% in after-hours trading, following a closing price of $13.63, down 14.11%. This volatility reflects market expectations for the upcoming clinical data release.
</li>
<li>
On April 25, analysts maintained a hold rating on Intellia, despite five stocks being considered better investment choices. Analysts' cautious stance may have some impact on the stock price. There is increasing attention on the gene editing industry, with noticeable capital inflow.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Onconetix is up 68.51% in pre-market trading. Based on recent key news:
<ol>
<li>
On April 24, Onconetix announced that Andrew Oakley resigned as chairman of the board and appointed Sammy Dorf as the new chairman. Following this announcement, the market reacted positively to the leadership change, significantly boosting the stock price.
</li>
<li>
On April 23, Onco-Innovations advanced its PNKP inhibitor technology's polymer testing, moving towards IND-enabled research. This technological progress has enhanced investor confidence in the company's future development, further driving up the stock price.
</li>
<li>
On April 24, Onconetix detailed changes in board and committee roles in SEC filings, including annual compensation approved by the compensation committee. These changes indicate adjustments in corporate governance structure, which the market reacted positively to, propelling the stock price upward. Significant technological advancements in the industry have bolstered investor confidence
Darkiris - CL, pre-market up 40.41%. Based on recent key news:
</li>
<li>
On April 24, Darkiris Inc. completed a private equity financing and acquisition deal. The company successfully completed a PIPE financing worth $3.8 million and acquired approximately $800,000 in premium film and television IP through equity issuance. This move enhances the company's strategic layout in the gaming and film sectors, driving up the stock price.
</li>
<li>
On April 24, Darkiris Inc. released detailed information about its &#34;Gaming + Film&#34; closed-loop strategy. By integrating key industry partners and high-quality content, combined with new funding and scalable AI post-production technology, the company aims to accelerate the commercialization of its AIGC platform, enhance the ecosystem synergy with gaming and media partners, and boost market confidence in its strategic transformation.
</li>
<li>
On April 24, Darkiris Inc. published original content on the EDGAR system, detailing the aforementioned transactions and strategies. This information further solidified investor confidence in the company's future development, leading to a significant increase in stock price. Recent market enthusiasm for tech stocks has driven up the prices of related stocks.
</li>
</ol>
Aditxt pre-market up 35.67%. Based on recent key news:
<ol>
<li>
On April 21, HRT Financial purchased 72,912 shares of Class A stock from Aditxt at a price of $0.33 per share. This move increased its shareholding ratio, demonstrating confidence in the company's future and driving up the stock price.
</li>
<li>
On April 22, HRT Financial sold 11,982 shares of Class A stock at a price of $0.30 per share. Despite some sales, the overall shareholding increased, and the market interpreted its actions as a positive signal, further supporting the stock price.
</li>
<li>
On April 23, Aditxt released relevant transaction information through the EDGAR system, increasing transparency and enhancing investor confidence, leading to a continued rise in stock price. The U.S. stock market has recently experienced increased volatility, and risks should be monitored
</li>
</ol>

CHSN

NTLA

Chanson pre-market down 22.48%; Intellia Therapeutics pre-market up 22.26%; Onconetix pre-market up 68.51%; Darkiris - CL pre-market up 40.41%; Aditxt pre-market up 35.67%

Pre-market hot trades in US stocks: Chanson pre-market down 22.48%; Intellia Therap pre-market up 22.26%